IRWD vs OIG Comparison

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.

Orion180 Insurance Group Inc operating as an insurance holding company. It is a founder-led, technology-focused, high-growth, high-margin specialty insurance group delivering insurance solutions with a growing footprint across the United States. The group operates in two segments: Services and Underwriting. The Services segment includes technology-enabled policy servicing operations, including intercompany revenue earned through service arrangements between the Services and Underwriting segments. The Underwriting segment includes a conventional, regulated insurance model focused on risk selection, pricing, and statutory capital management. The segment also includes a segregated cell designed to assume reinsurance risk.